



China Pharma Holdings

中国医药控股有限公司

*A Fully Integrated Modern Pharmaceutical Company
with R&D, Production and Sales Strength*

Contents

01



Company Profile

02



Production

03



Sales

04



Products

05



R&D

China Pharma Holdings Profile

Listed on NYSE American

A Professional Pharmaceutical Manufacturer Located in Hainan Free Trade Port

- Develop, manufacture and market a diversified portfolio of products.
- Focus on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases.
- Cost-effective business model driven by market demand and supported by The Year 2011 GMP Standards product lines covering the major dosage forms.
- Distribution network across all major cities and provinces in China.
- Product pipeline directly aligned with policies.
- Considerable growth opportunities related to favorable Hainan Free Trade Port policies.

Hainan Helpson Medical & Biotechnology Co., Ltd.

A wholly owned subsidiary of China Pharma, located in Hainan Free Trade Port, has nearly 30 years of experience in the Chinese pharmaceutical industry



- **Production:** Multiple new GMP certified production lines provide a variety of formulations capacity (freeze-dried powder injectables, liquid injectables, tablets, capsules, granules)
- **Diversified Product Portfolio:** 20 branded and general drugs, nutritional supplements, innovative medical devices
- **Nationwide Distribution Network:** Covers 30 provinces and cities, long-term relationships with public hospitals
- **R&D:** Diversified product pipeline, make full use of industry expertise and Hainan Free Trade Port preferential policies
- **Growth Opportunities:** Pharmaceuticals pipeline products, innovative medical devices and nutritional supplements

Visionary Founder



Zhilin Li, Chairwoman, CEO

- China Pharma Holdings, Inc. (NYSE: CPHI) CEO
- Chairman and CEO of Helpson since 1993
- Vice President of National Health Industry Business Management Association
- Executive Vice President of Hainan Province Pharmaceutical Industry Association
- Served as President to Haikou Institute of Biological Engineering
- United Business Institutes (UBI) - Doctorate in Business Administration
- Graduated from Sichuan University, with a degree in biology

*Safeguarding Human Health, Improving the Quality of Life,
Building Shareholder Value*

Industry Background

Development Opportunities & Challenges



Promulgation of New Pharmaceutical Industry Policies in Recent Years :

- The Drug Administration Act has been amended to encourage innovation
- Marketing Authorization Holder (MAH)
- Consistency evaluation
- Healthcare activities via Internet
- Healthcare reform
- Centralized procurement
- To establish a new model of healthcare in Hainan

Key Industrial Developments:

Provide high-quality and affordable medical solutions



Advanced Production Capabilities

- ✓ Freeze-dried powder injectable production line
- ✓ Liquid injectable production line
- ✓ Oral solution production line
- ✓ Medical device production line
- ✓ Nutritional supplement production line

State-of-the-Art Production Facility

New GMP Production Facilities



Advanced Capacity

New GMP Level, Highest Standards in Chinese
Pharmaceutical Manufacturing Industry



Injectable Production Lines

Dried Powder Injectables

Liquid Injectables



Oral Solution Production Line

Tables

Capsules

Granules

(Cefaclor Only Lines)



Medical Device Production Line

Type I , II

Surgical Mask

Medical Mask

KN95 Mask

Sprayer



Supplements Production Line

Tables, Capsules, Granule,
oral liquid

Injectable Production Lines

Advanced Technology, Capacity to Support High Volumes




Two Freeze-Dried Powder Injectables Production Lines

- Located in new production building
- Received new GMP certification in 2014


Two Liquid Injectables Production Lines

- Located in new building
- Received new GMP certification in 2014
- One production with $F_0 > 8$; the with other $F_0 < 8$



Nutrition & Supplements Production Line

Foods for Special Medical Purpose (FSMP), Nutrition & Supplements



New GMP Standards Certification Production Facilities

- Plant environment and ancillary facilities are GMP certified production level
- Capsule, Tablet, and Granule

For Self-Owned Products Manufacture and OEM

- For manufacture of Helpson's products
- High standard production facilities to undertake domestic and international OEM





Effective Sales

- ✓ Nearly 30 years experience
- ✓ Proven academic promotional team
- ✓ Sales & Marketing network across China

Sales & Marketing

Nationwide Sales Network with Significant Market Share in Public Hospitals

B. Sales Via Internet

To develop of the "Internet + medical" new model

A. Network

Based on the nationwide sales of prescription drugs;
Marketing network covers China's major basic level healthcare institutes



C. Flat Sales Structure

Long-term implementation of flat sales structure
In line with the recent policy guidance

E. Teamwork

Experienced sales team
Professional academic promoting staff
16 sales offices, 30 provinces, more than 1,000 representatives

D. Competitive Advantage

Sales networks established over two decades ago
Creates competitive barrier

National Sales & Distribution Network

Headquartered in Haikou, 16 Sales Offices in Key Markets, Covering 30 Provinces



Highly Populated Geographic Markets

Our Drugs Positioned to Serve Large Provinces and Cities



Si, CQ



JS,ZJ



NE China



SD,HN



Strong Product Portfolio

- ✓ For high morbidity diseases
- ✓ Diversified product portfolio
- ✓ Differentiated form of drug release

Strong Product Positioning

Demand Closely Linked to Population, Demographics & Prevalence

For High Morbidity Diseases

Leveraging advanced science and technology for the human benefit



Classic Generics

Promote post patent drugs with excellent clinical manifestations

Differentiated Drug Release Form

Optimize the product dosage form, more suitable for the medication needs of special patients




Children's Medication

Care of children's health

Targeted dosage forms and drug release form design

Innovative formula

Focus of new drug R&D formulations with intellectual property rights



Nutrition Supplements

Meet evolving needs, health conditioning, disease prevention





Medical Devices

Helping fight COVID-19

Market Analysis


Large Addressable Market, Extensive Growth Drivers

- ✓ Total health spend and pharmaceutical sales in China forecast to grow by 8.20% and 9.8% in 2021, respectively.
- ✓ Growth is driven by a combination of continued strong macro-economic growth and favorable demographics, as well as a continued rise in household incomes.
- ✓ Upgrade 1,000 county-level hospitals to Class III hospitals in 2018-20, and more in batches in outer years.
- ✓ Most provinces aim to achieve >90% local treatment rate by end-2020; Henan plans to add 162 Class III hospitals by 2025 vs ~1000 now; Guangdong sets construction for +150 hospitals.
- ✓ Local governments allocate fiscal budget to upgrade medical equipment and capabilities, with an acceleration from COVID-19.
- ✓ Domestic products are generally preferred, and sometimes required, given their better price/quality trade-off



Diversified Product Portfolio

20 Existing Products Provide Revenue Stability, Visibility and Growth



Anti-Infective & Respiratory

7 Products account for 50-60% of total revenue
Cerebrovascular disease, neurasthenia, hypertension

CNS, Cardiovascular & Cerebrovascular

7 Products account for 20-30% of total revenue
Antibiotics, antibacterial, cold & flu

Digestive

Four existing products
Contribute ~10% of total revenue
For liver disease, stomach disease

Others

Two existing products
Contribute 10-20% of total revenue: Vitamins, Wound recovery

Cardiovascular & Cerebrovascular



Ozagrel

For acute thrombotic cerebral infarction and cerebral infarction associated with dyskinesia



Bumetanide

For the treatment of heart failure, liver disease, kidney disease edema



Candesartan

For essential hypertension



Gastrodin

For neurasthenia, neurasthenic syndrome and vascular neuropathic headache embolism, traumatic brain syndrome, vertigo such as Meniere's disease

China Pharma (NYSE: CPHI)



CerebroteinHydrolysate

Cerebral thrombosis, cerebral hemorrhage, traumatic brain injury, stroke, brain surgery, encephalitis and meningitis sequelae, memory impairment, nervous breakdown, neurological headache and Alzheimer's disease



Polysaccharide Sodium

Ischemic heart, cerebrovascular disease (cerebral thrombosis, cerebral embolism, coronary heart disease, etc.) and hyperlipidemia

Anti-Infective & Respiratory



Pusen OK®

Cold symptomatic treatment of drugs used to relieve cold, nasal congestion caused by allergic rhinitis, runny nose, fever, headache



Cefaclor

For respiratory infections caused by sensitive bacteria such as pneumonia, bronchitis etc.



Roxithromycin

For pyogenes and tonsillitis caused by Streptococcus pyogenes, sinusitis caused by susceptible bacteria, otitis media, Mycoplasma pneumoniae, or pneumonia caused by Chlamydia pneumoniae



Clarithromycin

Applies to the following infections caused by clarithromycin sensitive bacteria lower respiratory tract infection



Andrographolide

Detoxification, anti-bacterial anti-inflammatory. For upper respiratory tract infection, bacillary dysentery



Cephalosporine

Suitable for acute tonsillitis, airway infections such as pharyngitis, otitis media, sinusitis and bronchitis caused by sensitive fungi; Pneumonia, respiratory infections, urinary tract infections and skin soft tissue infections.

Digestive, Hepatitis & Other Health



Tiopronin

Acute and chronic Hepatitis B, and for the relief of drug-induced liver injury.



Hepatocyte Growth Promoting Factors

Serious viral hepatitis symptoms caused by various viral hepatitis types (acute, subnormal temperature, chronic serious disease early or middle period of hepatitis)



Omeprazole

Gastroesophageal reflux disease, and other conditions caused by excess acidic formulations in the stomach, including gastric ulcers, recurrent duodenal ulcers and Zollinger-Ellison Syndrome.



Vitamin B6 for Injection

Vitamin supplement



Granisetron Hydrochloride

Nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors



Compound Ammonium Glycyrrhetate S

Liver dysfunction caused by acute and chronic hepatitis; supplemental treatment to toxic/trauma hepatitis, liver cancer; also for the indication of food/drug poisoning, and drug allergy

Personal Protective Products



KN95 Particulate Respirator

Implementation standard GB2626:2019 KN95.
Rate of non-oily particulate filtration efficiency $\geq 95\%$
3D, 5-layer design



75% Alcohol Wash-free Sanitizer

Disinfection care for bacteria on the hands and surfaces of various objects
Produced by pharmaceutical manufacturer
Wash-free & fast-drying
Portable, efficient sprayer



Disposable Medical Mask

Class II Medical Devices Registration; CE Registered
Implementation standard EN14683:2019
Rate of bacterial filtration efficiency $\geq 95\%$
Flat, 3-layer



Particle Filtering Half Mask

Meets the requirements of Regulation(EU)2016/425. Tested according to EN 149:2001+A1:2009 FFP1 NR
Rate of Penetration of filter material $\leq 20\%$
3D, 5-layer design



Disposable Surgical Mask

Class II Medical Devices
Rate of bacterial filtration efficiency $\geq 95\%$
Flat, 3-layer

High-Quality Noni Enzyme Products

An edible and medicinal tropical plant, *Haematsu halberd* (Noni) Noni stock solution is rich in SOD antioxidant enzymes and enzymes, nourishing the pineal gland, the human body hormone to maintain a positive state




Noni, scientific name *Morinda Citrifolia*, also known as *Haematsu halberd*, *Haemonchus Mori*; Found in seasonal fruit, radish, Indian mulberry.

Rich in important functional ingredients such as cenonin, polysaccharides, quinones, terpenes and alkaloids.

Experimental data show that Noni fruit may positively effect immune system regulation, inhibition of tumor growth, anti-oxidation, anti-aging, free radical scavenging, anti-inflammatory and other effects, including high blood lipids, high blood sugar, diabetes and other diseases.


Hainan Island is Noli's only growing site in China and is listed as China's national new resource food



We Leverage State-of-the-Art Biotech Production and Geographic Advantages of Hainan Island

Valuable Product Pipeline

More than 20 Years of Reporting to the CFDA



Pipeline Product – NMN+PQQ

Anti-aging, Non-drug Intervention – Special Medicine Food, Nutritional Supplements

NMN, known as β -niacin single nucleotide, is a precursor to the synthetic life factor NAD+.

The NAD+ molecule is an important support for cell vitality, and since NAD+ cannot be absorbed directly by the human body, it needs to be converted by supplementing NMN. NAD+, also known as coenzyme I, or niacinamide adenine dinucleotide, participates in cellular reactions.

NAD+ is an important coenzyme for energy metabolism in many aerobic organisms, including humans, which promotes the metabolism of sugars, fats, and amino acids and participates in many important cellular processes as signaling molecules.

- ✓ NMN has the effect of delaying aging
- ✓ PQQ can improve the metabolism and growth function of biological tissue
- ✓ NMN + PQQ combination can promote mitochondrial energy supply and mitochondrial regeneration



Pipeline Product – NMN+PQQ

Anti-aging, Non-drug Intervention – Special Medicine Food, Nutritional Supplements

In the human body, NMN is the most direct precursor to NAD+, and its function is embodied through NAD+.

The decline in NAD+ during aging is considered to be the leading cause of diseases and disabilities, such as hearing and vision loss, cognitive and motor dysfunction, immunodeficiency, arthritis, metabolic disorders and cardiovascular disease caused by autoimmune inflammatory response disorders.

In a variety of cell metabolic reactions, NAD+ plays an important role in the cell to maintain vitality of an important support.

By maintaining sufficient NAD+ in the cell, DNA self-healing can be maintained, so that the DNA damage caused by aging can be effectively repaired, thereby inhibiting aging.

- ✓ Supplementing NMN increases NAD+ level in the body
- ✓ Delay, improve, and prevent a variety of manifestations associated with aging
- ✓ Suitable for age-induced metabolic disorders, chronic diseases and geriatric diseases



Hainan Free Trade Port

Expect Considerable Increase in Growth Opportunities

- ✓ 22 specific measures were put forth in five areas, including:
- ✓ **Development of Internet Prescription Drug Sales.** Set up Hainan e-prescription center to provide third-party information services for prescription drug sales agencies. For prescription drugs already on the market in China, except for drugs that are explicitly subject to special management under the National Drug Administration Law, all are allowed to be sold on the Internet by relying on electronic prescription centers and will no longer be approved separately.
- ✓ **Increased Drug Market Access.** This measure is in line with previous policies, including the “Guiding Principles for Real-World Evidence in Support of Drug Development and Review (Trial)” published on 3 January 2020, and the Boao Lecheng Real World Data Research and Innovation Center established in Boao Lecheng on April 10, 2020.
- ✓ **Development of Hainan’s High-End Medical Beauty Industry.** Beauty medical institutions in Boao Lecheng can now sell and use in bulk medical products that already being sold in the U.S., EU, Japan, and other countries.
- ✓ **Optimization of Access and Development Environment for the Transplant Science Field.** This policy is conducive to the pioneering development of advanced technology in Hainan
- ✓ **Transformation of Universities Scientific Research in Hainan, including but not limited to marine science.** This will allow China Pharma and others to now take full advantage of marine resources, which has seen significant global investment and R&D over the years, to further develop and commercialize products.
- ✓ **Increased Agriculture Market Access.** This is beneficial to China Pharma as it will allow for use of tropical plant resources and leverage geographic advantages of nutritional products, where China Pharma has a competitive advantage.



Hainan Free Trade Port

Potential growth engine for our future business

- ✓ According to the General Plan for the Construction of Hainan Free Trade Port, issued on June 1, 2020, "Goods entering the Mainland from Hainan Free Trade Port shall, in principle, go through the relevant formalities in accordance with the import regulations and levy customs duties and import link taxes in accordance with the regulations." For goods produced by enterprises that do not contain imported materials or contain imported materials that are processed and value-added in Hainan Free Trade Port by more than 30% (including 30%), import duties shall be exempted from entering the Mainland by 'second-tier' and import link value-added tax and consumption tax shall be levied in accordance with the regulations."
 - If imported materials are used in production and processed at Hainan Free Trade Port, the value added of processing exceeds or reaches 30%, then its goods can be exempted from tax when they enter the Mainland.
 - For foreign companies with sales scale in China, we are open to cooperation based on this policy advantage
-
- ✓ On November 11, 2020, the Ministry of Finance, the General Administration of Customs and the General Administration of Taxation jointly issued the Notice on the "Zero Tariff" Policy on Raw Materials of Hainan Free Trade Port and issued the List of "Zero Tariffs" Of Raw Materials of Hainan Free Trade Port
 - This policy applies only to enterprises registered at Hainan Free Trade Port and have independent legal personality
 - For domestic enterprises that import raw materials, we are open to cooperation with the advantages of this policy



China Pharma Holdings (NYSE: CPHI)

THANK YOU

www.chinapharmaholdings.com

China Pharma Holdings, Inc.
Ms. Diana Na Huang
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com

Global IR Partners
David Pasquale
New York Office Phone: +1-914-337-8801
CPHI@Globalirpartners.com